Novartis/Sandoz make history with 1st US biosimilar Zarxio
This article was originally published in Scrip
Executive Summary
Novartis and its Sandoz unit made history on 6 March, gaining the first approval of a biosimilar in the US – Zarxio (filgrastim-sndz).